Evidence map›Paper›PMID 41081599›Full record

ArticleMolecular cancer research : MCR2026

Combined MYC Activation and PTEN Loss Drives Molecular Features of Aggressive Preinvasive Lesions in Mouse Prostate.

Michael Rubenstein, Apurv Rege, Gretchen Hubbard, Danielle Cannady, Shreya Agarwal, Kevin Chen, Alex Estrada, Carolina Gomes-Alexandre, Jessica Hicks, Tracy Jones and 4 more

Abstract read
In one paragraph

Article in Molecular cancer research : MCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michael RubensteinDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0004-4382-9342
Apurv RegeDepartment of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland.ORCID 0009-0007-8337-7100
Gretchen HubbardCaris Life Sciences, Phoenix, Arizona.ORCID 0009-0002-2774-9428
Danielle CannadyDepartment of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland.ORCID 0009-0008-7032-8825
Shreya AgarwalDepartment of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland.ORCID 0000-0002-5926-7063
Kevin ChenDepartment of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland.ORCID 0000-0003-4250-8518
Alex EstradaDepartment of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland.ORCID 0009-0009-0169-4407
Carolina Gomes-AlexandreDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0006-5476-7137
Jessica HicksDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-7885-3319
Tracy JonesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0002-2882-4274
Qizhi ZhengDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0004-9366-8997
Srinivasan YegnasubramanianDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-0744-6606
Charles J BieberichDepartment of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland.ORCID 0000-0002-9208-5077
Angelo M De MarzoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4847-5307

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI NELSON, WILLIAM GEORGE · 1992 to 2020
$43.9M
Translational imaging biomarkers of the tumor microenvironment in early prostate cancerU54CA274370 · NCI · JOHNS HOPKINS UNIVERSITY · PI Alexander S Szalay · 2022 to 2026
$9.1M
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African AncestryU01CA196390 · NCI · JOHNS HOPKINS UNIVERSITY · PI DE MARZO, ANGELO MICHAEL, PIENTA, KENNETH J. · 2015 to 2020
$5.8M
Commonwealth Fund (CF)DOD Prostate Cancer Research Program (PCRP) W81XWH-18-2-0015Irving A. Hansen Memorial FoundationNational Cancer Institute (NCI) CA006973National Cancer Institute (NCI) CA196390National Cancer Institute (NCI) CA274370National Cancer Institute (NCI) P50CA58236NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA058236NCI NIH HHS U01 CA196390NCI NIH HHS U54 CA274370Patrick C. Walsh Prostate Cancer Research Fund (Patrick C Walsh Prostate Cancer Research Fund)
6 · The paper itself

Abstract

Prostate cancer ranges from indolent to rapidly progressive. An elevated cell proliferation index portends poor outcomes, yet the molecular alterations essential for increased cell proliferation remain ill-defined. Gain of MYC combined with biallelic PTEN loss predicts prostate cancer mortality. Prior studies have shown that combined MYC overexpression and Pten loss, driven by the Hoxb13 locus, results in prostatic intraepithelial neoplastic (PIN) lesions that progress to metastatic disease (BMPC mice). Yet, single gene alterations in these mice result only in PIN lesions. In this study, we performed transcriptomic profiling of PIN lesions from each of the three genotypes. Whereas MYC alone resulted in increases in genes related to cell-cycle regulation/cell division, combined MYC and Pten loss led to a further and more consistent increase and a synergistic cell-cycle progression. Increased ribosome biogenesis/translation is required for cell proliferation. Whereas MYC alone increased 45S rRNA and most components of the translation machinery, these were more strongly induced in BMPC mice. Surprisingly, Pten loss alone resulted in a downregulation of translation machinery genes, which could explain the absence of biallelic PTEN loss in human PIN lesions and early carcinomas. Some MYC targets were increased only after Pten loss, indicating Pten loss increases MYC activity. IMPLICATIONS: Increased cell cycle and translational machinery gene induction may explain the synergy between MYC and PTEN loss for increasing prostate cancer cell proliferation and disease aggressiveness. These results provide further support for the therapeutic targeting of translation in prostate cancer.

Indexed as

Prostatic Intraepithelial NeoplasiaProstatic NeoplasmsProto-Oncogene Proteins c-mycPTEN PhosphohydrolaseAnimalsCell ProliferationGene Expression Regulation, NeoplasticHumansMaleMiceMyc protein, mouseProto-Oncogene Proteins c-mycPTEN PhosphohydrolasePten protein, mouse

Identifiers

PMID41081599
PMCPMC13482967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.